# Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: LCTX
Company: Lineage Cell Therapeutics
Source: Lineage Cell Therapeutics
Published: 2026-05-12 20:01 EST
Original Source URL: https://investor.lineagecell.com
## Summary

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative Treated Second Chronic SCI Patient in OPC1 DOSED Device

## Article Body
Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative Treated Second Chronic SCI Patient in OPC1 DOSED Device
## Recent Company News
- 2026-05-12 20:01 EST — [Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Lineage Cell Therapeutics
- 2026-05-05 12:00 EST — [Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026) — Source: Lineage Cell Therapeutics
- 2026-05-04 12:00 EST — [OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026](https://biopharmsignal.com/news/LCTX/opregenr-3-year-results-in-patients-with-ga-presented-at-foundation-fighting-blindness-retinal-innovation-summit-2026) — Source: Lineage Cell Therapeutics
- 2026-04-13 12:00 EST — [Lineage Announces Formation of Scientific Advisory Board](https://biopharmsignal.com/news/LCTX/lineage-announces-formation-of-scientific-advisory-board) — Source: Lineage Cell Therapeutics
- 2026-03-24 12:00 EST — [Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease](https://biopharmsignal.com/news/LCTX/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease) — Source: Lineage Cell Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)